Hikma Pharmaceuticals Plc (OTC:HKMPF) has been given an average rating of “Hold” by the seven research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company.

A number of equities research analysts recently issued reports on HKMPF shares. ValuEngine upgraded shares of Hikma Pharmaceuticals Plc from a “hold” rating to a “buy” rating in a report on Thursday, July 27th. Morgan Stanley reissued an “equal weight” rating on shares of Hikma Pharmaceuticals Plc in a research report on Tuesday, August 8th. Numis Securities Ltd reissued an “add” rating on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 19th. Jefferies Group LLC raised shares of Hikma Pharmaceuticals Plc from an “underperform” rating to a “hold” rating in a research report on Monday, August 21st. Finally, Goldman Sachs Group, Inc. (The) lowered shares of Hikma Pharmaceuticals Plc from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 22nd.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/15/hikma-pharmaceuticals-plc-hkmpf-receives-average-rating-of-hold-from-analysts.html.

Hikma Pharmaceuticals Plc (OTC:HKMPF) opened at 15.65 on Friday. The firm has a 50-day moving average price of $16.64 and a 200 day moving average price of $21.87. Hikma Pharmaceuticals Plc has a 52-week low of $15.10 and a 52-week high of $28.80. The stock has a market capitalization of $3.76 billion and a price-to-earnings ratio of 22.68.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Analyst Recommendations for Hikma Pharmaceuticals Plc (OTC:HKMPF)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.